Balyasny Asset Management
CNCE

Balyasny Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Balyasny Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,995
Closed -$275K – 2250
2018
Q1 		$275K Sell
11,995
-2,570
-18% -$57.2K ﹤0.01% 1643
2017
Q4 		$377K Buy
14,565
+3,000
+26% +$60.4K ﹤0.01% 1648
2017
Q3 		$171K Buy
+11,565
New +$168K ﹤0.01% 1728

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management's CNCE Position: Q2 2018 in Review

Balyasny Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 11,995 shares — an estimated $275K sold.

Balyasny Asset Management first reported a position in CNCE in Q3 2017 and held it in 3 quarters. The position peaked at $377K in Q4 2017. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

  • Balyasny Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 11,995 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $275K.
  • Balyasny Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
  • Balyasny Asset Management's Concert Pharmaceuticals, Inc. position peaked at $377K in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.